Oculis Holding AG (NASDAQ:OCS) Given Average Rating of “Buy” by Brokerages

Oculis Holding AG (NASDAQ:OCS) has been assigned an average recommendation of “Buy” from the six research firms that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $30.17.

Several research firms recently weighed in on OCS. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Tuesday, June 11th. Robert W. Baird raised their target price on shares of Oculis from $35.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, June 11th. HC Wainwright boosted their target price on shares of Oculis from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Wedbush reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th. Finally, Bank of America cut their price objective on Oculis from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, June 11th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OCS. Compagnie Lombard Odier SCmA raised its stake in shares of Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares in the last quarter. abrdn plc acquired a new position in shares of Oculis in the 4th quarter valued at $15,980,000. Finally, Searle & CO. bought a new position in shares of Oculis during the 4th quarter worth about $112,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Price Performance

NASDAQ OCS opened at $11.70 on Friday. The company has a quick ratio of 4.71, a current ratio of 4.71 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $473.85 million, a PE ratio of -6.57 and a beta of 0.30. Oculis has a 12-month low of $9.05 and a 12-month high of $14.50. The company has a 50 day moving average price of $12.03 and a two-hundred day moving average price of $11.84.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). Oculis had a negative return on equity of 52.72% and a negative net margin of 6,712.02%. The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.28 million. As a group, equities analysts predict that Oculis will post -1.92 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.